---
title: "Cell Metab | BRAF-V600E靶向治疗耐药机制：转硫代谢的重编程"
date: 2025-03-22T06:37:00Z
draft: ["false"]
tags: [
  "fetched",
  "BioArtMED"
]
categories: ["Acdemic"]
---
Cell Metab | BRAF-V600E靶向治疗耐药机制：转硫代谢的重编程 by BioArtMED
------
<div><section data-mpa-powered-by="yiban.io"><span leaf=""><img data-imgfileid="505239779" data-ratio="0.153125" data-src="https://mmbiz.qpic.cn/mmbiz_gif/PlqGiacEDZrl6ZIRYNQA4RCImTMicRrbv5sPcELibpQBIhP5NZojwrw88POsJPxkSBTtianhPFh8odYBjPGicPd0pCg/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1" data-type="gif" data-w="640" src="https://mmbiz.qpic.cn/mmbiz_gif/PlqGiacEDZrl6ZIRYNQA4RCImTMicRrbv5sPcELibpQBIhP5NZojwrw88POsJPxkSBTtianhPFh8odYBjPGicPd0pCg/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1"></span></section><p data-mpa-action-id="m7yt31i8109f"><strong mpa-font-style="m7yt34o7o6e"><span leaf=""><span textstyle="">撰文 | 染色体</span></span></strong></p><p data-mpa-action-id="m7yt31i8109f"><strong mpa-font-style="m7yt34o7o6e"><span leaf=""><br></span></strong></p><p data-mpa-action-id="m7yt31i81gen"><span leaf="" mpa-font-style="m7yt34o7khd" data-mpa-action-id="m7yt8efl112q"><span textstyle="">黑色素瘤是一种高度侵袭性的皮肤癌，约50%的患者携带BRAF-V600E突变，该突变导致MAPK/ERK信号通路异常激活，促进癌细胞增殖</span></span><span mpa-font-style="m7yt8k4pu8h" data-mpa-action-id="m7yt8k4yyev"><span leaf="">【1】</span></span><span mpa-font-style="m7yt34o7khd" data-mpa-action-id="m7yt8n7n1oty"><span leaf=""><span textstyle="">。BRAF-V600E抑制剂</span><span textstyle="">（如vemurafenib和dabrafenib）</span><span textstyle="">已成为治疗这一突变黑色素瘤的主要靶向治疗手段</span></span><span mpa-font-style="m7yt8n6wky9"><span leaf="">【2】</span></span><span data-mpa-action-id="m7yt8ocoa0y"><span leaf=""><span textstyle="">。然而，尽管初期治疗效果显著，大多数患者最终会出现耐药性，导致疾病复发</span></span><span mpa-font-style="m7yt8oc26h8"><span leaf="">【3】</span></span><span leaf=""><span textstyle="">。</span></span></span></span></p><p data-mpa-action-id="m7yt31i81zm6"><span leaf="" mpa-font-style="m7yt34o71obe"><br></span></p><p data-mpa-action-id="m7yt31i8puc"><span leaf="" mpa-font-style="m7yt34o71lam"><span textstyle="">近日，来自匈牙利国家肿瘤生物学实验室的</span></span><strong mpa-font-style="m7yt34o71vuf"><span leaf=""><span textstyle="">Péter Nagy</span></span></strong><span leaf="" mpa-font-style="m7yt34o71bdt"><span textstyle="">团队在</span></span><strong mpa-font-style="m7yt34o71d8y"><em><span leaf=""><span textstyle="">Cell Metabolism</span></span></em></strong><span leaf="" mpa-font-style="m7yt34o710hl"><span textstyle="">期刊发表题为</span></span><strong mpa-font-style="m7yt34o7bik"><em><span leaf=""><span textstyle="">Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma</span></span></em></strong><span leaf="" mpa-font-style="m7yt34o71492"><span textstyle="">（转硫通路驱动黑色素瘤中BRAF-V600E靶向治疗耐药性的研究）</span><span textstyle="">的文章。</span></span><strong mpa-font-style="m7yt34o71zw"><span leaf=""><span textstyle="">研究表明，在BRAF抑制剂（BRAFi）治疗下，胱硫醚γ裂合酶（CSE）的上调和胱硫醚β-合成酶（CBS）的抑制在耐药黑色素瘤细胞中发挥了关键作用，促进了细胞存活和肿瘤生长。研究还发现，联合使用CSE抑制剂D,L-丙炔基甘氨酸（PAG）与BRAFi，可以有效延缓耐药的出现，为BRAF V600E突变患者的耐药治疗提供了新的策略。</span></span></strong></p><p data-mpa-action-id="m7yt31i8ihr"><span leaf="" mpa-font-style="m7yt34o72ot"><br></span></p><section data-mpa-action-id="m7yt7hrs1ha" nodeleaf=""><img data-backh="195" data-backw="545" data-imgfileid="505343540" data-ratio="0.35833333333333334" data-src="https://mmbiz.qpic.cn/mmbiz_png/PlqGiacEDZrlYOS69HyiaXYdmWExh5UicPWjjM4WiaKUib7YuLkrmgZ4cdgJiaHPFriazqoeicZ9VbFuo3YY1IcWWofv8A/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/PlqGiacEDZrlYOS69HyiaXYdmWExh5UicPWjjM4WiaKUib7YuLkrmgZ4cdgJiaHPFriazqoeicZ9VbFuo3YY1IcWWofv8A/640?wx_fmt=png&amp;from=appmsg"></section><p data-mpa-action-id="m7yt31i81tnm"><span leaf="" mpa-font-style="m7yt34o71c5c"><br></span></p><p data-mpa-action-id="m7yt31i81ymu"><span leaf="" mpa-font-style="m7yt34o7jkx" data-mpa-action-id="m7yt8vi8gk6"><span textstyle="">BRAF-V600E抑制剂通过促使黑色素瘤细胞代谢从有氧糖酵解转向线粒体呼吸，导致活性氧</span><span textstyle="">（ROS）</span><span textstyle="">水平升高并改变氧化还原环境，这一变化在耐药性形成过程中发挥了关键作用</span></span><span mpa-font-style="m7yu7ol71un3" data-mpa-action-id="m7yu7ola12zv"><span leaf="">【4】</span></span><span leaf="" mpa-font-style="m7yt34o7jkx" data-mpa-action-id="m7yt8vi8gk6"><span textstyle="">。</span></span></p><p data-mpa-action-id="m7yt31i81ymu"><span leaf="" mpa-font-style="m7yt34o7jkx"><br></span></p><p data-mpa-action-id="m7yt31i8l3u"><strong mpa-font-style="m7yt34o71ki0"><span leaf=""><span textstyle="">耐药性中的氧化还原适应机制</span><span textstyle="">  </span></span></strong></p><p data-mpa-action-id="m7yt31i8793"><span leaf="" mpa-font-style="m7yt34o71z96"><br></span></p><p data-mpa-action-id="m7yt31i8793"><span leaf="" mpa-font-style="m7yt34o71z96"><span textstyle="">首先，研究人员发现，BRAF-V600E突变的黑色素瘤细胞在接受BRAF和MEK抑制剂</span><span textstyle="">（DT治疗）</span><span textstyle="">治疗后，会经历显著的氧化还原变化，并通过代谢重编程适应治疗压力。DT治疗通过抑制BRAF/MEK/ERK信号通路，导致ROS水平升高，从而引发细胞氧化损伤。为了应对这一压力，黑色素瘤细胞通过上调抗氧化酶如超氧化物歧化酶</span><span textstyle="">（SOD2）</span><span textstyle="">、硫氧还蛋白还原酶</span><span textstyle="">（TrxR1）</span><span textstyle="">和谷胱甘肽过氧化物酶</span><span textstyle="">（GPX1、GPX4）</span><span textstyle="">，来维持氧化还原稳态。然而，这种适应机制有限，DT治疗的细胞对外源性过氧化氢</span><span textstyle="">（H</span></span><sub mpa-font-style="m7yt34o71jz0"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o71wjo"><span textstyle="">O</span></span><sub mpa-font-style="m7yt34o713x1"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o710ba"><span textstyle="">）</span><span textstyle="">变得更为敏感，表明抗氧化储备已经大量消耗，导致细胞更容易受到进一步氧化应激的损伤。与此同时，DT治疗还促使细胞代谢发生重塑，从糖酵解转向线粒体氧化磷酸化，增强了三羧酸循环和电子传递链的活性，提升了ATP的生成，但也加剧了ROS的积累。因此，细胞必须通过激活磷酸戊糖途径增加NADPH的供应，以增强抗氧化能力。这种代谢调整有助于细胞应对DT引发的氧化应激，维持生存并提高耐药性。在耐药细胞</span><span textstyle="">（DTR）</span><span textstyle="">中，这一适应机制进一步优化，糖酵解活性恢复，ROS积累减少，细胞重新进入增殖状态。DTR细胞的代谢重编程表明，尽管DT治疗初期能够有效抑制细胞增殖，但随着抗氧化和代谢调节的持续进行，癌细胞最终克服了DT带来的压力，恢复了生长，并形成了耐药性。</span></span></p><p data-mpa-action-id="m7yt31i8793"><span leaf="" mpa-font-style="m7yt34o710ba"><br></span></p><p data-mpa-action-id="m7yt31i81a26"><strong mpa-font-style="m7yt34o72bz"><span leaf=""><span textstyle="">转硫通路在耐药性中的作用</span></span></strong><span leaf="" mpa-font-style="m7yt34o79en"><span textstyle=""> </span></span></p><p data-mpa-action-id="m7yt31i81a26"><span leaf="" mpa-font-style="m7yt34o79en"><br></span></p><p data-mpa-action-id="m7yt31i81zb9"><span leaf="" mpa-font-style="m7yt34o71lry"><span textstyle="">除了氧化还原适应，研究人员发现转硫通路在耐药性形成中起着关键作用。该通路通过CBS和CSE调节半胱氨酸</span><span textstyle="">（Cys）</span><span textstyle="">的代谢。DT治疗下，黑色素瘤细胞显著上调CSE的表达，增强了硫化氢</span><span textstyle="">（H</span></span><sub mpa-font-style="m7yt34o71o8n"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o7g6m"><span textstyle="">S）</span><span textstyle="">和多硫化物</span><span textstyle="">（Cys-SSH）</span><span textstyle="">的生成。这些活性硫化物</span><span textstyle="">（RSS）</span><span textstyle="">通过调节氧化还原状态、增强线粒体代谢并抑制氧化损伤，帮助细胞适应DT治疗带来的压力，提升存活能力。研究还发现，DT处理的细胞摄取更多的半胱氨酸，并将其用于合成GSH和H</span></span><sub mpa-font-style="m7yt34o7dex"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o71btg"><span textstyle="">S。然而，细胞内游离半胱氨酸的水平却下降，表明它们迅速进入抗氧化和能量代谢通路。在DTR细胞中，CSE表达下降，CBS水平恢复，表明耐药细胞可能不再依赖CSE生成的RSS，而是通过其他途径维持生存。例如，DTR细胞表现出更高的GSH水平和抗氧化能力，以防止铁死亡</span><span textstyle="">（ferroptosis）</span><span textstyle="">，同时恢复糖酵解活性，增强能量供给。H</span></span><sub mpa-font-style="m7yt34o7fkz"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o7r4j"><span textstyle="">S在黑色素瘤细胞中的作用较为复杂，外源性H</span></span><sub mpa-font-style="m7yt34o7gzi"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o7180x"><span textstyle="">S可抑制Akt和ERK通路，诱导细胞周期停滞并促使细胞凋亡，而内源性H</span></span><sub mpa-font-style="m7yt34o713ff"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o7h00"><span textstyle="">S及其多硫化物则具有促瘤作用。H</span></span><sub mpa-font-style="m7yt34o711c7"><span leaf=""><span textstyle="">2</span></span></sub><span leaf="" mpa-font-style="m7yt34o7ctz"><span textstyle="">S通过增强线粒体代谢、调节氧化还原状态和抑制铁死亡，帮助细胞提高对DT治疗的耐受性。</span></span></p><p data-mpa-action-id="m7yt31i81zb9"><span leaf="" mpa-font-style="m7yt34o7ctz"><br></span></p><p data-mpa-action-id="m7yt31i8893"><strong mpa-font-style="m7yt34o71ypf"><span leaf=""><span textstyle="">靶向CSE的联合治疗策略</span></span></strong><span leaf="" mpa-font-style="m7yt34o7ws7"><span textstyle=""> </span></span></p><p data-mpa-action-id="m7yt31i818go"><span leaf="" mpa-font-style="m7yt34o71bnv"><br></span></p><p data-mpa-action-id="m7yt31i818go"><span leaf="" mpa-font-style="m7yt34o71bnv"><span textstyle="">由于CSE在DT耐药性形成中的关键作用，研究人员认为抑制CSE是一种潜在的联合治疗策略。研究显示，在BRAF-V600E抑制剂的基础上联合CSE抑制剂PAG，可以显著降低耐药细胞的存活率，并有效延缓耐药性的形成。在黑色素瘤小鼠模型中，联合治疗显著延长了无进展生存期</span><span textstyle="">（PFS）</span><span textstyle="">，并抑制了肿瘤的生长。临床研究也进一步验证了这一机制，发现DT治疗期间患者的CSE表达显著升高，表明CSE上调可能是癌细胞应对压力的适应机制。因此，联合CSE抑制剂可能成为提高BRAF-V600E靶向治疗效果的重要策略。</span></span></p><p data-mpa-action-id="m7yt31i81md9"><span leaf="" mpa-font-style="m7yt34o7wyk"><br></span></p><p data-mpa-action-id="m7yt31i83b8"><span leaf="" mpa-font-style="m7yt34o717sj"><span textstyle="">综上所述，该研究</span></span><strong mpa-font-style="m7yt34o775d"><span leaf=""><span textstyle="">揭示了黑色素瘤细胞在DT治疗压力下，通过氧化还原适应和转硫通路的调节，成功适应了治疗环境，并最终发展出耐药性。深入理解这些机制不仅有助于揭示DT耐药的本质，还为开发更有效的联合治疗策略提供了新的思路。</span></span></strong></p><p data-mpa-action-id="m7yt31i83b8"><strong mpa-font-style="m7yt34o775d"><span leaf=""><br></span></strong></p><section data-mpa-action-id="m7yt31i81kgy" nodeleaf=""><img data-backh="558" data-backw="562" data-imgfileid="505343541" data-ratio="0.9920870425321464" data-src="https://mmbiz.qpic.cn/mmbiz_png/PlqGiacEDZrlYOS69HyiaXYdmWExh5UicPWT2KVkxg1H2ibWmoaVsqoO5kpGBm6uUr45jGiblXq88PhHq5o6MJqsCTQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1011" src="https://mmbiz.qpic.cn/mmbiz_png/PlqGiacEDZrlYOS69HyiaXYdmWExh5UicPWT2KVkxg1H2ibWmoaVsqoO5kpGBm6uUr45jGiblXq88PhHq5o6MJqsCTQ/640?wx_fmt=png&amp;from=appmsg"></section><p data-mpa-action-id="m7yt31i81v7x"><span leaf="" mpa-font-style="m7yt34o7vtq"><br></span></p><p data-mpa-action-id="m7yt31i8l3j"><strong mpa-font-style="m7yt76nc1t8t"><span leaf=""><span textstyle="">原文链接：</span></span></strong></p><p data-mpa-action-id="m7yt31i81ns4"><strong mpa-font-style="m7yt76ncrf3"><span leaf=""><span textstyle="">https://doi.org/10.1016/j.cmet.2025.01.02</span></span></strong></p><p><span><span leaf=""><br></span></span></p><p><span><span leaf="">制版人：十一</span></span></p><section><span><span leaf=""><br></span></span></section><section><section><section><span leaf=""><br></span></section><section><section><p><strong><span><span leaf="">参考文献</span></span></strong></p></section></section><section><span leaf=""><br></span></section></section></section><p data-mpa-action-id="m7yt31i8khy" data-pm-slice="2 2 []"><span leaf="" mpa-font-style="m7ytaupno6o"><span textstyle="">[1] Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002). Mutations of the BRAF gene in human cancer. </span></span><strong mpa-font-style="m7ytaupo8r5"><em><span leaf=""><span textstyle="">Nature</span></span></em></strong><span leaf="" mpa-font-style="m7ytaupo1wc4"><span textstyle=""> 417, 949-954. https://doi.org/10.1038/nature00766.</span></span></p><p data-mpa-action-id="m7yt31i8121k"><span leaf="" mpa-font-style="m7ytaupobmd"><span textstyle="">[2] Sosman, J.A., Kim, K.B., Schuchter, L., Gonzalez, R., Pavlick, A.C., Weber, J.S., McArthur, G.A., Hutson, T.E., Moschos, S.J., Flaherty, K.T., et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.</span></span><strong mpa-font-style="m7ytaupo10r9"><em><span leaf=""><span textstyle=""> N. Engl. J. Med.</span></span></em></strong><span leaf="" mpa-font-style="m7ytaupoiqq"><span textstyle=""> 366, 707-714. https://doi.org/10.1056/NEJMoa1112302.</span></span></p><p data-mpa-action-id="m7yt31i8ifl"><span leaf="" mpa-font-style="m7ytaupo2lm"><span textstyle="">[3] Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. </span></span><strong mpa-font-style="m7ytaupo2g5"><em><span leaf=""><span textstyle="">Nature</span></span></em></strong><span leaf="" mpa-font-style="m7ytaupo8b4"><span textstyle=""> 483, 100-103. https://doi.org/10.1038/nature10868.</span></span></p><p data-mpa-action-id="m7yt31i889m"><span leaf="" mpa-font-style="m7ytaupoisp"><span textstyle="">[4] Featherston, T., Paumann-Page, M., and Hampton, M.B. (2024). Melanoma redox biology and the emergence of drug resistance. Adv. Cancer Res. 162, 145-171. https://doi.org/10.1016/bs.acr.2024.06.004.</span></span></p><p><span leaf=""><br></span></p><p><span><strong><span leaf="">学术合作组织</span></strong></span></p><p><span><span leaf="">（*排名不分先后）</span></span></p><p><span leaf=""><img data-imgfileid="505343388" data-ratio="0.912962962962963" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrkWPklx8lHMSO4yMxHuGop6en1g1DwcsO87IQPR6FibTHCAQTuN974AxEolhJuXvuvS5nXqFpYlKSQ/640?wx_fmt=jpeg&amp;from=appmsg" data-type="jpeg" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrkWPklx8lHMSO4yMxHuGop6en1g1DwcsO87IQPR6FibTHCAQTuN974AxEolhJuXvuvS5nXqFpYlKSQ/640?wx_fmt=jpeg&amp;from=appmsg"></span></p><p><strong><strong><span leaf=""><br></span></strong></strong></p><p><strong><strong><span leaf="">战略合作伙伴</span></strong></strong></p><section data-role="outer" label="edit by 135editor"><section data-role="outer" label="edit by 135editor"><section mpa-from-tpl="t"><section data-id="75" data-plugin="layout2boxes" mpa-from-tpl="t"><section data-copyright="" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><span><span leaf="">（*排名不分先后）</span></span></section></section></section></section></section></section></section></section></section><section data-role="outer" label="edit by 135editor"><section data-id="75" data-plugin="layout2boxes" mpa-from-tpl="t"><section data-copyright="" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><mp-common-profile data-pluginname="mpprofile" data-index="2" data-from="2" data-id="MzA3Mzg1OTgzMw==" data-is_biz_ban="0" data-origin_num="773" data-biz_account_status="0"></mp-common-profile></section></section></section></section></section></section></section></section></section></section><p><span><span leaf="">（*排名不分先后）</span></span></p><section data-role="outer" label="edit by 135editor"><section mpa-from-tpl="t"><section data-id="75" data-plugin="layout2boxes" mpa-from-tpl="t"><section data-inner-id="75" data-inner-name="135editor-layout2boxes" mpa-from-tpl="t"><section mpa-from-tpl="t"><span leaf="">·</span></section><section data-copyright="" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section data-id="63" data-plugin="officialaccountcard" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section leaf=""><mp-common-profile data-pluginname="mpprofile" data-index="2" data-from="2" data-id="MzA3Mzg1OTgzMw==" data-is_biz_ban="0" data-origin_num="773" data-biz_account_status="0"></mp-common-profile></section></section></section><section mpa-from-tpl="t"><section mpa-from-tpl="t"><svg viewbox="0 0 320 200" mpa-from-tpl="t"></svg></section></section></section></section></section></section></section><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section data-id="63" data-plugin="officialaccountcard" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section leaf=""><mp-common-profile data-pluginname="mpprofile" data-index="3" data-from="2" data-id="MzkzMzIxNDc1NA==" data-is_biz_ban="0" data-origin_num="60" data-biz_account_status="0"></mp-common-profile></section></section></section><section mpa-from-tpl="t"><section mpa-from-tpl="t"><svg viewbox="0 0 320 200" mpa-from-tpl="t"></svg></section></section></section></section></section></section></section></section><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section data-id="63" data-plugin="officialaccountcard" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section leaf=""><mp-common-profile data-pluginname="mpprofile" data-index="2" data-from="2" data-id="MzIyNDY2NDM1Mg==" data-is_biz_ban="0" data-origin_num="773" data-biz_account_status="0"></mp-common-profile></section></section></section><section mpa-from-tpl="t"><section mpa-from-tpl="t"><svg viewbox="0 0 320 200" mpa-from-tpl="t"></svg></section></section></section></section></section></section></section></section></section></section></section></section><section data-role="outer" label="edit by 135editor"><section mpa-from-tpl="t"><section data-id="75" data-plugin="layout2boxes" mpa-from-tpl="t"><section data-inner-id="75" data-inner-name="135editor-layout2boxes" mpa-from-tpl="t"><section mpa-from-tpl="t"><span leaf="">·</span></section><section data-copyright="" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section data-id="63" data-plugin="officialaccountcard" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><span></span></section></section></section></section></section></section></section></section></section></section></section></section><section data-role="outer" label="edit by 135editor"><section data-id="75" data-plugin="layout2boxes" mpa-from-tpl="t"><section data-copyright="" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><mp-common-profile data-pluginname="mpprofile" data-index="2" data-from="2" data-id="MzA3Mzg1OTgzMw==" data-is_biz_ban="0" data-origin_num="773" data-biz_account_status="0"></mp-common-profile></section></section></section></section></section></section></section></section></section></section><section><section><section powered-by="xiumi.us"><section><section><p><span><strong><strong><span leaf="">转载须知</span></strong></strong></span></p><p><span><strong><strong><span leaf=""><br></span></strong></strong></span></p><p><span><span><span><span leaf="">【原创文章】BioArt原创文章，</span></span><span><span leaf="">欢迎个人转发分享，未经允许禁止转载，所刊登的所有作品的著作权均为BioArt所拥有。BioArt保留所有法定权利，违者必究。</span></span></span></span></p></section></section></section></section></section><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><span leaf=""><br></span></section></section></section></section><p powered-by="xiumi.us"><span leaf=""><br></span></p><section><section powered-by="xiumi.us"><section><section><section powered-by="xiumi.us"><span leaf=""><br></span></section><section powered-by="xiumi.us"><span leaf=""><br></span></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><a href="http://mp.weixin.qq.com/s?__biz=MzA3MzQyNjY1MQ==&amp;mid=2652713314&amp;idx=1&amp;sn=0cc85a6bdb731800a253adbb35540700&amp;chksm=84e6a2d6b3912bc005642f4921186b1e7d65016022079d2bcef3c1e77a038bb696dd41b20299&amp;scene=21#wechat_redirect" imgurl="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70x3kzG7nBk0GJOBPPLQFXf8HiaxznqCM9iaL8QGAvwRdibkjIPZm9Bpugw/640?wx_fmt=jpeg&amp;from=appmsg" linktype="image" tab="innerlink" data-itemshowtype="0" target="_blank" data-linktype="1"><span><img data-src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70x3kzG7nBk0GJOBPPLQFXf8HiaxznqCM9iaL8QGAvwRdibkjIPZm9Bpugw/640?wx_fmt=jpeg&amp;from=appmsg" data-ratio="1" data-s="300,640" data-type="jpeg" data-w="438" data-imgfileid="505242439" src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70x3kzG7nBk0GJOBPPLQFXf8HiaxznqCM9iaL8QGAvwRdibkjIPZm9Bpugw/640?wx_fmt=jpeg&amp;from=appmsg"></span></a></section></section><section powered-by="xiumi.us"><p><strong><span leaf="">BioArt</span></strong></p></section></section><section><section powered-by="xiumi.us"><section><a href="http://mp.weixin.qq.com/s?__biz=MzA3MzQyNjY1MQ==&amp;mid=2652713314&amp;idx=3&amp;sn=acc44f3103e24cc44d8355f6d6ef2088&amp;chksm=84e6a2d6b3912bc0b261bacc5d397c4e068ae71c2cd35173731020b7cb2604479a2df04b7810&amp;scene=21#wechat_redirect" imgurl="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj7028O7984AWiaho5icgTjnZHT7qiaoquVBHHZErlvvsJD9iaaRNGCrAwvUUw/640?wx_fmt=jpeg&amp;from=appmsg" linktype="image" tab="innerlink" data-itemshowtype="0" target="_blank" data-linktype="1"><span><img data-src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj7028O7984AWiaho5icgTjnZHT7qiaoquVBHHZErlvvsJD9iaaRNGCrAwvUUw/640?wx_fmt=jpeg&amp;from=appmsg" data-ratio="1" data-s="300,640" data-type="jpeg" data-w="640" data-imgfileid="505242435" src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj7028O7984AWiaho5icgTjnZHT7qiaoquVBHHZErlvvsJD9iaaRNGCrAwvUUw/640?wx_fmt=jpeg&amp;from=appmsg"></span></a></section></section><section powered-by="xiumi.us"><p><strong><span leaf="">Med</span></strong></p></section></section><section><section powered-by="xiumi.us"><section><a href="http://mp.weixin.qq.com/s?__biz=MzA3MzQyNjY1MQ==&amp;mid=2652713314&amp;idx=2&amp;sn=5b07f2fce73921afcde12c915e859d20&amp;chksm=84e6a2d6b3912bc086c3286fb50c8421211f843d8990fccffe89bfb7a020d409275a22f32520&amp;scene=21#wechat_redirect" imgurl="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70MvZQNIGD1fYO5WxgRdudH5iaP84rAuCpbE4bHJOAIRib1X35vD5M2ggg/640?wx_fmt=jpeg&amp;from=appmsg" linktype="image" tab="innerlink" data-itemshowtype="0" target="_blank" data-linktype="1"><span><img data-src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70MvZQNIGD1fYO5WxgRdudH5iaP84rAuCpbE4bHJOAIRib1X35vD5M2ggg/640?wx_fmt=jpeg&amp;from=appmsg" data-ratio="1" data-s="300,640" data-type="jpeg" data-w="495" data-imgfileid="505242441" src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70MvZQNIGD1fYO5WxgRdudH5iaP84rAuCpbE4bHJOAIRib1X35vD5M2ggg/640?wx_fmt=jpeg&amp;from=appmsg"></span></a></section></section><section powered-by="xiumi.us"><p><strong><span leaf="">Plants</span></strong></p></section></section><section><section powered-by="xiumi.us"><section><a href="http://mp.weixin.qq.com/s?__biz=MzA3MzQyNjY1MQ==&amp;mid=2652713314&amp;idx=4&amp;sn=1071bf9e9799a59f6dd362b69ca520ef&amp;chksm=84e6a2d6b3912bc07a30ff86b00fd4c1258afed5e368cd33aa98c515f75d91caab5d190bbb4d&amp;scene=21#wechat_redirect" imgurl="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70ytp3ic0icHE0wMzHuau9IiboiaribibibQkBANjxSC0Be0vNSoiaU3Z8gdJrSg/640?wx_fmt=jpeg&amp;from=appmsg" linktype="image" tab="innerlink" data-itemshowtype="0" target="_blank" data-linktype="1"><span><img data-src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70ytp3ic0icHE0wMzHuau9IiboiaribibibQkBANjxSC0Be0vNSoiaU3Z8gdJrSg/640?wx_fmt=jpeg&amp;from=appmsg" data-ratio="1" data-s="300,640" data-type="jpeg" data-w="640" data-imgfileid="505242440" src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj70ytp3ic0icHE0wMzHuau9IiboiaribibibQkBANjxSC0Be0vNSoiaU3Z8gdJrSg/640?wx_fmt=jpeg&amp;from=appmsg"></span></a></section></section><section powered-by="xiumi.us"><p><strong><span leaf="">人才招聘</span></strong></p></section></section><section><section powered-by="xiumi.us"><section><a href="http://mp.weixin.qq.com/s?__biz=MzA3MzQyNjY1MQ==&amp;mid=2652713314&amp;idx=5&amp;sn=fac01a4697df1b991748d231ece257ab&amp;chksm=84e6a2d6b3912bc03f3c170a02367c61b5b02f5e280e41f0696675b7385a6cda93612277015c&amp;scene=21#wechat_redirect" imgurl="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj709BeZo59oessPDNd17zRDGFkXYORLvntxFAf25d7TzzbDoXfb42gcMQ/640?wx_fmt=jpeg&amp;from=appmsg" linktype="image" tab="innerlink" data-itemshowtype="0" target="_blank" data-linktype="1"><span><img data-src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj709BeZo59oessPDNd17zRDGFkXYORLvntxFAf25d7TzzbDoXfb42gcMQ/640?wx_fmt=jpeg&amp;from=appmsg" data-ratio="1" data-s="300,640" data-type="jpeg" data-w="494" data-imgfileid="505242442" src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrletTN5O8opicic6BVia3ktj709BeZo59oessPDNd17zRDGFkXYORLvntxFAf25d7TzzbDoXfb42gcMQ/640?wx_fmt=jpeg&amp;from=appmsg"></span></a></section></section><section powered-by="xiumi.us"><p><strong><span leaf="">会议资讯</span></strong></p></section></section></section></section><section><span leaf=""><br></span></section><p><span leaf=""><br></span></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><p><strong><span leaf="">近期直播推荐</span></strong></p></section></section></section><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section powered-by="xiumi.us"><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section></section></section><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section><span leaf=""><br></span></section></section></section></section></section><p><span leaf=""><br></span></p></section><p><span leaf=""><img data-backh="254" data-backw="578" data-croporisrc="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrnJEy3iacXAOIAoQYMh6Hf6Xq4AaE3TEvh6sWfeCdrmL8YibFCwoiapGEGsza0vJ5AsiaLhKInIfIe78Q/0?wx_fmt=jpeg&amp;from=appmsg" data-cropselx2="578" data-cropsely2="255" data-imgfileid="505343697" data-ratio="0.4398148148148148" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrnJEy3iacXAOIAoQYMh6Hf6Xq4AaE3TEvh6sWfeCdrmL8YibFCwoiapGEGsza0vJ5AsiaLhKInIfIe78Q/640?wx_fmt=jpeg&amp;from=appmsg" data-type="jpeg" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_jpg/PlqGiacEDZrnJEy3iacXAOIAoQYMh6Hf6Xq4AaE3TEvh6sWfeCdrmL8YibFCwoiapGEGsza0vJ5AsiaLhKInIfIe78Q/640?wx_fmt=jpeg&amp;from=appmsg"></span></p><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/-loXV1HlEjn4IU8h65Yq_A",target="_blank" rel="noopener noreferrer">原文链接</a>
